Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 02190) disclosed a share repurchase of 85,000 H shares on 21 May 2026, according to its Next Day Disclosure Return filed the same day.

The shares were bought on the Hong Kong Stock Exchange at prices ranging from HK$20.74 to HK$21.24, translating to a volume-weighted average of roughly HK$20.95 and a total consideration of HK$1.78 million.

Post-transaction, issued shares outstanding (excluding treasury stock) fell by 0.0254% to 326.81 million. Treasury shares increased to 9.54 million, while the company’s total issued share count remained unchanged at 336.35 million.

The buyback forms part of a mandate approved on 13 May 2026 that allows the repurchase of up to 32.72 million shares. Cumulative purchases under this mandate now stand at 396,000 shares, representing 0.1182% of the company’s issued capital as at the mandate date.

Under Hong Kong listing rules, Zylox-Tonbridge is restricted from issuing new shares or disposing of treasury shares until 20 June 2026.